U.S. Supreme Court Declines To Review Rulings That Invalidate United Therapeutics' Patent; Decisions That Liquidia Does Not Infringe Any Valid Claims Of The Three Patents Originally Asserted By United Therapeutics Are Now Final And Not Subject To Further Appeal
Portfolio Pulse from Benzinga Newsdesk
The U.S. Supreme Court has declined to review rulings that invalidate United Therapeutics' patent, confirming that Liquidia does not infringe any valid claims of the patents originally asserted by United Therapeutics. This decision is final and not subject to further appeal.
October 07, 2024 | 2:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Liquidia Corporation has successfully defended against United Therapeutics' patent claims, as the U.S. Supreme Court declined to review the rulings. This final decision removes legal uncertainties for Liquidia, potentially boosting investor confidence.
The Supreme Court's decision not to review the case confirms Liquidia's non-infringement, removing legal uncertainties and potentially leading to a positive market reaction as investors gain confidence in Liquidia's legal standing.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
NEGATIVE IMPACT
United Therapeutics faces a setback as the U.S. Supreme Court declines to review rulings invalidating its patent claims against Liquidia. This final decision could negatively impact United Therapeutics' market position.
The Supreme Court's decision not to review the case is a setback for United Therapeutics, as it confirms the invalidation of their patent claims. This could negatively impact their market position and investor sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90